Immunosuppressive treatment for proliferative lupus nephritis

Overview of attention for article published in Cochrane database of systematic reviews, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 1 news story.

The Food and Drug Administration has approved belimumab (Benlysta) for treating active lupus nephritis (LN) in children aged 5-17…